The selective activity of anthracyclines in HER2-amplified breast cancer could be related to the simultaneous amplification of the Top2a gene, the main target of anthracyclines, placed in the same amplicon as the HER2/neu gene. This evidence concerns the gene TOP2A and breast carcinoma.